[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335468-105":59,"doc-detail-335468-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","unveiling-the-prognostic-significance-of-malignant-ascites-in-advanced-gastrointestinal-cancers-a-marker-of-peritoneal-carcinomatosis-burden-medical-oncology-original-research","Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers - a marker of peritoneal carcinomatosis burden - medical oncology original research","","Ascites is common in advanced gastrointestinal cancers with peritoneal metastases (PM) and worsens survival, yet the specific relationship between malignant ascites, PM, and outcomes has been insufficiently studied. This retrospective analysis pools prospectively collected clinical trial data in metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGC) with PM. Results show malignant ascites defines a high-risk subgroup with inferior progression-free and overall survival, and higher peritoneal disease burden. The study concludes that tailored research strategies are needed.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unveiling-the-prognostic-significance-of-malignant-ascites-in-advanced-gastrointestinal-cancers-a-marker-of-peritoneal-carcinomatosis-burden-medical-oncology-original-research/335468/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unveiling-the-prognostic-significance-of-malignant-ascites-in-advanced-gastrointestinal-cancers-a-marker-of-peritoneal-carcinomatosis-burden-medical-oncology-original-research/335468.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address regarding ascites in advanced GI cancers?","Question",{"text":112,"@type":113},"Ascites is frequent in advanced gastrointestinal cancers with peritoneal metastases and negatively affects survival, but prior studies had not specifically quantified how malignant ascites relates to PM and survival outcomes in metastatic colorectal and gastric cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the analyses conducted in metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGC)?",{"text":117,"@type":113},"The study used two pooled analyses: mCRC data from two Italian randomized trials with systemic-therapy eligible patients, and gastric cancer/peritoneal metastasis data from patients receiving both systemic and peritoneal-directed therapies.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key outcome findings for patients with malignant ascites?",{"text":121,"@type":113},"In mCRC, patients with PM and malignant ascites had significantly worse progression-free and overall survival than those without PM, while patients with PM but no ascites did not show similarly increased hazard. In gastric cancer/peritoneal metastasis, malignant ascites corresponded to higher peritoneal cancer index scores and inferior overall survival.",{"name":123,"@type":110,"acceptedAnswer":124},"What conclusion does the study draw about malignant ascites?",{"text":125,"@type":113},"Malignant ascites identifies a subgroup of patients with peritoneal metastases who experience poor outcomes, supporting the need for tailored research approaches.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},335468,1790668146,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":4},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TherapeuTic advances in  \nMedical Oncology Original Research  \nUnveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden  \nLeonardo Provenzano*, Yong Xiang Gwee*, Veronica Conca*, Sara Lonardi, Silvia Bozzarelli, Emiliano Tamburini, Alessandro Passardi, Alberto Zaniboni, Federica Tosi, Giuseppe Aprile, Vincenzo Nasca, Alessandra Boccaccino, Margherita Ambrosini, Guglielmo Vetere, Martina Carullo, Marcello Guaglio,  \nLuigi Battaglia, Joseph Jonathan Zhao, Daryl Kai Ann Chia, Wei Peng Yong, Patrick Tan, Jimmy So, Guowei Kim, Asim Shabbir, Chin-Ann Johnny Ong, Francesco Casella, Chiara Cremolini\\#, Maria Bencivenga\\#, Raghav Sundar\\# and Filippo Pietrantonio\\#  \nAbstract  \nBackground: Ascites is common in advanced gastrointestinal cancers with peritoneal metastases (PM) and negatively impacts patient survival. No study to date has specifically evaluated the relationship between ascites, PM and survival outcomes in metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGC) .  \nObjectives: This study aims to investigate and elucidate the relationship between malignant ascites, PM and survival outcomes in both mCRC and mGC patients.  \nDesign: This is a retrospective analysis of prospectively collected clinical trial data of mCRCand mGC patients with PM.  \nMethods: We performed two pooled analyses, firstly of two Italian randomized trials enrolling patients with mCRC eligible for systemic therapy (TRIBE2; VALENTINO), and secondly of gastric cancer and peritoneal metastasis (GCPM) patients who underwent bi-directional therapeutic treatment comprising systemic and peritoneal-directed therapies.  \nResults: Of 900 mCRC patients, 39 (4 .3%) had PM with malignant ascites. Compared to the group without PM, median progression-free and overall survival were significantly inferior in the ascites group (hazard ratio (HR) for progression-free survival (PFS) 1. 68, 95% confidence interval (CI): 1.21–2.35, p =0 . 007; HR for overall survival (OS) 2. 14, 95% CI: 1.57–3. 01, p \u003C 0. 001), but not in the group of PM without ascites (HR for PFS 1. 10, 95% CI: 0.91 – 1.34; HR for OS 1. 04, 95% CI: 0.84 – 1.30) . Of 170 patients with GCPM, those with ascites had higher median Peritoneal Cancer Index scores (23 vs 9, p \u003C 0. 001) . Median OS was significantly inferior among those with ascites compared to those without (13 .0 vs 21.0 months, HR 1. 71, 95% CI: 1.16–2. 52, p = 0 . 007) .  \nConclusion: Ascites identifies a subgroup of patients with PM and poor outcomes, for whom tailored research are needed.  \nKeywords: chemotherapy, gastric cancer, intraperitoneal chemotherapy, medical oncology, precision oncology, prognostic biomarker, systemic treatment, targeted therapy  \nReceived: 25 May 2024; revised manuscript accepted: 19 September 2024.  \nTherAdv Med Oncol 2024, Vol. 16: 1–14  \nDOI: 10. 1177/ 17588359241289517 © The Author(s), 2024.  \nArticle reuse guidelines: [sagepub.com/journals](sagepub.com/journals)permissions  \nCorrespondences to:  \nFilippo Pietrantonio  \nMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G.Venezian, 1, Milan 20133, Italy  \nfilippo.pietrantonio@ istitutotumori.mi.it  \nRaghav Sundar  \nDepartment of Haematology–Oncology, National University Cancer Institute, 1E Kent Ridge Road, Singapore 119228, Singapore  \nSingapore Gastric Cancer Consortium, Singapore, Singapore  \nCancer and Stem Cell Biology Program, DukeNUS Medical School, Singapore, Singapore  \nYong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore The N.1 Institute for Health, National University of Singapore, Singapore, Singapore  \n[raghav.sundar@yale.edu](raghav.sundar@yale.edu)  \nLeonardo Provenzano Vincenzo Nasca Margherita Ambrosini  \nMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy  \nYong Xiang Gwee  \nJoseph Jonathan Zhao  \nDepartment of Haematology–Oncology, National Uni","cbCait1dAFI3Z85K","https://ap.wps.com/l/cbCait1dAFI3Z85K","pdf",974431,14,"English","# Abstract\n## Background\n## Objectives\n## Design\n## Methods\n## Results\n## Conclusion\n## Keywords\n## Correspondences","[{\"question\":\"What problem does the study address regarding ascites in advanced GI cancers?\",\"answer\":\"Ascites is frequent in advanced gastrointestinal cancers with peritoneal metastases and negatively affects survival, but prior studies had not specifically quantified how malignant ascites relates to PM and survival outcomes in metastatic colorectal and gastric cancer.\"},{\"question\":\"How were the analyses conducted in metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGC)?\",\"answer\":\"The study used two pooled analyses: mCRC data from two Italian randomized trials with systemic-therapy eligible patients, and gastric cancer/peritoneal metastasis data from patients receiving both systemic and peritoneal-directed therapies.\"},{\"question\":\"What were the key outcome findings for patients with malignant ascites?\",\"answer\":\"In mCRC, patients with PM and malignant ascites had significantly worse progression-free and overall survival than those without PM, while patients with PM but no ascites did not show similarly increased hazard. In gastric cancer/peritoneal metastasis, malignant ascites corresponded to higher peritoneal cancer index scores and inferior overall survival.\"},{\"question\":\"What conclusion does the study draw about malignant ascites?\",\"answer\":\"Malignant ascites identifies a subgroup of patients with peritoneal metastases who experience poor outcomes, supporting the need for tailored research approaches.\"}]","Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers - a marker of peritoneal carcinomatosis burden - medical oncology original research | PDF",1790011078,35]